Robert Vestal
Ophthalmology · Memphis, TNNPI 1245720069
Payments from drug & device makers
What this record shows
This record is dominated by education: $5,361 of the $8,546 with a category attached, or 62.7%. Rxsight Inc accounts for 64.8% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2023 at $6,200 and has fallen 81.8% since, to $1,127 in 2025.
Across 133 payments — averaging $64.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$6K
- AbbVie$462
- Alcon$404
- Harrow Eye, LLC$374
- Bausch & Lomb Americas Inc.$305
- Apellis Pharmaceuticals, Inc.$231
- plus $1K from 15 others
What the payments were for
- Food & beverage$3,18537%
- Education$5,36163%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 12 | $5,539 |
| AbbVie | 20 | $462 |
| Alcon | 11 | $404 |
| Harrow Eye, LLC | 15 | $374 |
| Bausch & Lomb Americas Inc. | 15 | $305 |
| Apellis Pharmaceuticals, Inc. | 11 | $231 |
| Amgen | 8 | $159 |
| Sight Sciences, Inc. | 1 | $134 |
| Ocular Therapeutix, Inc. | 6 | $133 |
| Rayner Intraocular Lenses Limited | 4 | $106 |
| Regeneron Healthcare Solutions, Inc. | 1 | $106 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $104 |
| ANI Pharmaceuticals, Inc. | 5 | $100 |
| Thea Pharma Inc. | 4 | $80 |
| Genentech USA, Inc. | 4 | $66 |
| Oyster Point Pharma, Inc. | 3 | $63 |
| Dompe US, Inc. | 2 | $58 |
| Biotissue Holdings Inc. | 2 | $40 |
| Glaukos Corporation | 2 | $35 |
| Novartis | 2 | $33 |
| Carl Zeiss Meditec USA, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,546 in reported general payments places this provider in the 85th percentile of 323 ophthalmology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 17 | $23,530 |
| RestasisCyclosporine | 17 | $23,390 |
| LumiganBimatoprost | 23 | $14,078 |
| Prednisolone Acetate | 113 | $4,477 |
| CombiganBrimonidine Tartrate/Timolol | 14 | $3,934 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 99 | $2,303 |
| Brimonidine Tartrate | 37 | $1,808 |
| Latanoprost | 151 | $1,554 |
| Ketorolac Tromethamine | 18 | $700 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 49 | $554 |
| MoxifloxacinMoxifloxacin Hcl | 24 | $492 |
| ValacyclovirValacyclovir Hcl | 21 | $475 |
| Timolol Maleate | 37 | $470 |
| Dorzolamide Hcl | 17 | $321 |
| ErythromycinErythromycin Base | 16 | $186 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $462 | $41,40254 claims |
| Bausch & Lomb Americas Inc.Xiidra | $305 | $23,53017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 323 ophthalmology providers in Tennessee.
Other ophthalmology in Memphis
- Melissa ToyosMemphis$1.3M
- Rolando ToyosMemphis$809K
- Brian FowlerMemphis$206K
- Brian JerkinsMemphis$150K
- James FreemanMemphis$141K
- John FreemanMemphis$136K
- Penny AsbellMemphis$131K
- Kourtney HouserMemphis$104K
- Subba GollamudiMemphis$67K
- Andrew CrothersMemphis$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.